Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIQP69)

• Drug Name: XR-9504 Drug Info
• Synonyms: XR-9504; CHEMBL258896; SCHEMBL7168501

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 22004473
  TTD Drug ID: DMIQP69

Molecule-Related Drug Atlas

Drug(s) Targeting Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[2]
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[3]
XR-9456	DMTUFI1	Discovery agent	N.A.	Investigative	[1]
XR-9544	DM1OZPN	Discovery agent	N.A.	Investigative	[1]
XR-9577	DMIZV6T	Discovery agent	N.A.	Investigative	[1]
Pyrrolopyrimidine	DMZLFVG	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Multidrug resistance protein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EDP-322	DMWTVM1	Bacterial infection	1A00-1C4Z	Phase 1	[5]
W-198	DMJ2R69	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
LY335979	DM2KITF	Acute myeloid leukaemia	2A60	Discontinued in Phase 3	[7]
CBT-1	DM097UP	Non-small-cell lung cancer	2C25.Y	Discontinued in Phase 3	[8]
Biricodar	DM65JCM	Ovarian cancer	2C73	Discontinued in Phase 2	[9]
Tariquidar	DMJG7VP	Adrenocortical carcinoma	2D11.Z	Discontinued in Phase 2	[10]
Elacridar	DMURVE8	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[11]
ONT-093	DMB8T5U	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[12]
TRISMETHOXYRESVERATROL	DM6USPC	Discovery agent	N.A.	Investigative	[13]
[1,1':2',1'']-terphenyl-4,3'',5''-triol	DMVOY4D	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Multidrug resistance protein 1 (ABCB1)	TT3OT40	MDR1_HUMAN	Inhibitor	[1]
Multidrug resistance-associated protein 1 (ABCC1)	TTOI92F	MRP1_HUMAN	Inhibitor	[1]

References

• [1] Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
• [2] Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40.
• [3] Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36.
• [4] Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4967-72.
• [5] In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother. 2015 Jan;70(1):173-7.
• [6] Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):558-63.
• [7] A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72.
• [8] A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512.
• [9] ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
• [10] Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Biochem Pharmacol.2008 Mar 15;75(6):1302-12.
• [11] 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. J Med Chem. 2008 Dec 11;51(23):7602-13.
• [12] A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5.
• [13] Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.